Meet Our Advisory Board Members

Jim is Principal Scientist, Preclinical Development at Aradigm in Hayward, CA, which is developing liquid formulations of inhaled therapeutics. He has over 30 years of aerosol R&D experience spanning the pharmaceutical, toxicological, clinical, and environmental fields.

Dr. Fitz-Gerald presently is an Assistant Professor in the Deptartment of Materials Science and Engineering at the University of Virginia and a co-founder of Nanotherapeutics. Dr. Fitz-Gerald expertise encompasses laser synthesized coatings and materials characterization of particulate and luminescent materials. Dr. Fitz-Gerald holds a Ph.D. and M.S. in Material Science and Engineering from the University of Florida and his B.S. in Mechanical Engineering from the University of Lowell.

Dr. Lalonde is a pre-clinical pharmacology and toxicology consultant with 20 years experience in pharmaceutical R&D at companies including Affymax Inc. and Nektar Therapeutics. This experience ranges from drug discovery and optimization to application of bioassays and animal models for candidate selection and development. He consults principally in the areas of immunology, infectious diseases and aerosol delivery.

Carl N. Kraus, M.D. is the Vice President, Scientific Affairs of the Infectious Diseases Research Center at PRA International, a global contract research organization and serves on multiple biotechnology advisory boards focusing on antiviral, antibacterial and countermeasure development programs. He previously created the Clinical Informatics group at i3/Ingenix that leveraged analytics in the drug development workflow as a risk mitigation process prior to study implementation. This group also served as a touchpoint for corporate innovation, fostering collaboration with informatics and technology providers. Dr. Kraus is a former Medical Officer of the Division of Special Pathogens in the Office of Antimicrobial Products, the US Food and Drug Administration where he was a primary reviewer for multiple INDs and NDAs in a variety of infectious diseases indications. He has more than 7 years experience in the pharmaceutical industry and is Board certified in Internal Medicine and Infectious Diseases by the American Board of Internal Medicine.

Dr. Roy presently is an assistant professor of Microbiology and Immunology at Tulane University School of Medicine, National Primate Research Center in New Orleans, Louisiana. Dr. Roy's work focuses on respiratory health and the aerobiology of airborne infectious diseases. His research is focused on characterization of the biological precursors and initial host response to disease agents transmitted by aerosol, with particular interest in pathogens considered to be biological threat agents, as well as naturally emerging infectious diseases that are aerosol transmissible. He has published over 35 original research articles and two book chapters in applied microbiology, high containment infectious disease research, medical product evaluation, and aerosol science. He holds a number of patents in the area of biomedical instrumentation. Prior to his appointment at Tulane University, he served as the Aerosol Sciences Team Leader at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Maryland. Concurrent to his tenure at USAMRIID, he cofounded Biaera Technologies, a biotechnology company; he subsequently sold rights in the company in 2006. Dr. Roy earned a M.S.P.H. (1993) and Ph.D. in Preventive Medicine (1999), from Tulane University School of Public Health and The University of Iowa College of Medicine, respectively.

Professor Gregory S. Schultz earned a Ph.D. degree in Biochemistry from Oklahoma State University in the area of hormonal regulation of breast cancer then completed three years of post-doctoral research in Cell Biology in the laboratory of Dr. James Jamieson at Yale University where he studied angiotensin binding to vascular smooth muscle cells. In 1979 he was appointed Assistant Professor of Biochemistry at the University of Louisville where he began studying growth factor regulation of normal and cancer cells. In 1989, he was appointed Professor of Obstetrics and Gynecology at the University of Florida where he established the multidisciplinary Institute for Wound Research.

Dr. Schultz has published more than 220 research papers, chapters and review articles that have been cited more than 6,400 times, and he has over a dozen patents in the area of wound healing. He has received over $11 million in grant funding from the National Institutes of Health, pharmaceutical companies, and the US Army, and he serves as an ad hoc member of NIH study sections. He served as President of the Wound Healing Society from 1999-2001, is the Chair of the Wound Bed Preparation Advisory Board, and serves on the National Pressure Ulcer Advisory Panel. He is on the editorial board of six journals in the areas of ocular and skin wound healing. He is a consultant for multiple biotechnology companies and a founder of QuickMed Technologies and Excaliard Pharmaceuticals.

In 2006 he was recognized by TIME magazine as an Innovation Leader in the area of microbicidal coatings, and in 2008 received the College of Medicine Basic Research Award.

Dr. Webb is a Professor of Clinical Pharmacology & Anesthesia in the Colleges of Veterinary Medicine and Medicine at the University of Florida. His research areas include pharmacodynamics and kinetics of drugs used in the peri-anesthesia period, making drugs available to minor species, and welfare of experimental subjects. He has published over 50 papers, 9 book chapters, and presented over 50 talks in the areas of anesthesia, veterinary medicine, and drug residue avoidance in food of animal origin at national and international meetings.